HC Wainwright reaffirmed their neutral rating on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a report issued on Tuesday, Marketbeat reports. They currently have a $75.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $72.00.

Several other research firms also recently weighed in on RARE. Zacks Investment Research raised Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research report on Tuesday, July 18th. SunTrust Banks, Inc. raised their price target on Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a buy rating in a research report on Wednesday, April 19th. Robert W. Baird reissued an outperform rating and set a $90.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 19th. Canaccord Genuity set a $98.00 price target on Ultragenyx Pharmaceutical and gave the stock a buy rating in a research report on Friday, July 28th. Finally, BidaskClub downgraded Ultragenyx Pharmaceutical from a buy rating to a hold rating in a research report on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company’s stock. Ultragenyx Pharmaceutical has a consensus rating of Hold and a consensus price target of $84.87.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 1.863% during mid-day trading on Tuesday, hitting $62.945. The company had a trading volume of 59,253 shares. Ultragenyx Pharmaceutical has a 12 month low of $51.67 and a 12 month high of $91.35. The firm has a 50-day moving average price of $65.29 and a 200 day moving average price of $67.43. The firm’s market capitalization is $2.67 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, topping the consensus estimate of ($1.73) by $0.01. During the same period in the previous year, the company posted ($1.46) EPS. On average, equities research analysts forecast that Ultragenyx Pharmaceutical will post ($7.24) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/ultragenyx-pharmaceutical-inc-rare-receives-neutral-rating-from-hc-wainwright.html.

In other Ultragenyx Pharmaceutical news, VP Theodore Alan Huizenga sold 480 shares of the business’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $57.46, for a total transaction of $27,580.80. Following the completion of the sale, the vice president now owns 9,366 shares of the company’s stock, valued at $538,170.36. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.20% of the stock is currently owned by insiders.

Large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. raised its stake in Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares in the last quarter. Prudential Financial Inc. raised its stake in Ultragenyx Pharmaceutical by 5.8% in the first quarter. Prudential Financial Inc. now owns 3,660 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 200 shares in the last quarter. Amalgamated Bank raised its stake in Ultragenyx Pharmaceutical by 4.6% in the first quarter. Amalgamated Bank now owns 4,628 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 202 shares in the last quarter. Tocqueville Asset Management L.P. raised its stake in Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 250 shares in the last quarter. Finally, Aperio Group LLC raised its stake in Ultragenyx Pharmaceutical by 8.4% in the second quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 299 shares in the last quarter. 95.40% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.